Botanix Pharmaceuticals' Topical Gel Launch Performs 'Exceptionally Well,' Euroz Hartleys Says

MT Newswires Live

4小时前

The launch of Botanix Pharmaceuticals' (ASX:BOT) topical gel, Sofdra, performed "exceptionally well" across multiple benchmarks, Euroz Hartleys said in a note on Wednesday.

Sofdra outperformed all of its peers on launches on prescriptions, and net sales per representative, despite starting with only 27 representatives in the first two quarters.

Adjusted for outcomes, Botanix operated 1.5 to 6 times more efficiently based on net sales generated per dollar of costs, compared with recent dermatology drug launches. The investment firm's analysis suggests that Sofdra has been the lowest-cost launch in the space.

Weekly prescription volumes in early September are tracking over 50% above those in August. The prescriptions seem to be tracking broadly in line with its September-quarter forecasts, per the note.

The investment firm maintained its buy recommendation and AU$0.44 per share price target on Botanix Pharmaceuticals.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2568944090"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568944090\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568944090?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-18 12:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568944090","market":"us","top_or_hot":-1,"title":"Botanix Pharmaceuticals' Topical Gel Launch Performs 'Exceptionally Well,' Euroz Hartleys Says","media":"MT Newswires Live","content":"<html><body><p> The launch of <a href=\"https://laohu8.com/S/BOT.AU\">Botanix Pharmaceuticals</a>' (ASX:BOT) topical gel, Sofdra, performed \"exceptionally well\" across multiple benchmarks, <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys said in a note on Wednesday.</p><p>Sofdra outperformed all of its peers on launches on prescriptions, and net sales per representative, despite starting with only 27 representatives in the first two quarters.</p><p>Adjusted for outcomes, Botanix operated 1.5 to 6 times more efficiently based on net sales generated per dollar of costs, compared with recent dermatology drug launches. The investment firm's analysis suggests that Sofdra has been the lowest-cost launch in the space.</p><p>Weekly prescription volumes in early September are tracking over 50% above those in August. The prescriptions seem to be tracking broadly in line with its September-quarter forecasts, per the note.</p><p>The investment firm maintained its buy recommendation and AU$0.44 per share price target on Botanix Pharmaceuticals.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Botanix Pharmaceuticals' Topical Gel Launch Performs 'Exceptionally Well,' Euroz Hartleys Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBotanix Pharmaceuticals' Topical Gel Launch Performs 'Exceptionally Well,' Euroz Hartleys Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-18 12:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> The launch of <a href=\"https://laohu8.com/S/BOT.AU\">Botanix Pharmaceuticals</a>' (ASX:BOT) topical gel, Sofdra, performed \"exceptionally well\" across multiple benchmarks, <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys said in a note on Wednesday.</p><p>Sofdra outperformed all of its peers on launches on prescriptions, and net sales per representative, despite starting with only 27 representatives in the first two quarters.</p><p>Adjusted for outcomes, Botanix operated 1.5 to 6 times more efficiently based on net sales generated per dollar of costs, compared with recent dermatology drug launches. The investment firm's analysis suggests that Sofdra has been the lowest-cost launch in the space.</p><p>Weekly prescription volumes in early September are tracking over 50% above those in August. The prescriptions seem to be tracking broadly in line with its September-quarter forecasts, per the note.</p><p>The investment firm maintained its buy recommendation and AU$0.44 per share price target on Botanix Pharmaceuticals.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BOT.AU","symbol_name":"BOTANIX PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568944090","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568944090","pubTimestamp":1758168019,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"The launch of Botanix Pharmaceuticals'  topical gel, Sofdra, performed \"exceptionally well\" across multiple benchmarks, Euroz Hartleys said in a note on Wednesday.Sofdra outperformed all of its peers on launches on prescriptions, and net sales per representative, despite starting with only 27 representatives in the first two quarters.Adjusted for outcomes, Botanix operated 1.5 to 6 times more efficiently based on net sales generated per dollar of costs, compared with recent dermatology drug launches. The investment firm's analysis suggests that Sofdra has been the lowest-cost launch in the space.Weekly prescription volumes in early September are tracking over 50% above those in August. The prescriptions seem to be tracking broadly in line with its September-quarter forecasts, per the note.The investment firm maintained its buy recommendation and AU$0.44 per share price target on Botanix Pharmaceuticals.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BOT.AU":"BOTANIX PHARMACEUTICALS LTD","BK7508":"医药生物股","BK7502":"大麻概念","BK7096":"制药"},"translate_title":"Euroz Hartleys表示，Botanix Pharmaceuticals推出的外用凝胶表现“非常好”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BOT.AU":1},"content_text":"The launch of Botanix Pharmaceuticals' (ASX:BOT) topical gel, Sofdra, performed \"exceptionally well\" across multiple benchmarks, Euroz Hartleys said in a note on Wednesday.Sofdra outperformed all of its peers on launches on prescriptions, and net sales per representative, despite starting with only 27 representatives in the first two quarters.Adjusted for outcomes, Botanix operated 1.5 to 6 times more efficiently based on net sales generated per dollar of costs, compared with recent dermatology drug launches. The investment firm's analysis suggests that Sofdra has been the lowest-cost launch in the space.Weekly prescription volumes in early September are tracking over 50% above those in August. The prescriptions seem to be tracking broadly in line with its September-quarter forecasts, per the note.The investment firm maintained its buy recommendation and AU$0.44 per share price target on Botanix Pharmaceuticals.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}